Provided by Tiger Trade Technology Pte. Ltd.

Maravai LifeSciences Holdings, Inc.

8.64
+0.35004.22%
Post-market: 8.57-0.0700-0.81%19:44 EDT
Volume:9.39M
Turnover:81.00M
Market Cap:2.24B
PE:-16.31
High:8.87
Open:8.28
Low:8.20
Close:8.29
52wk High:8.87
52wk Low:2.28
Shares:259.67M
Float Shares:103.00M
Volume Ratio:1.36
T/O Rate:9.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5299
EPS(LYR):-0.9059
ROE:-33.05%
ROA:-5.71%
PB:10.96
PE(LYR):-9.54

Loading ...

Company Profile

Company Name:
Maravai LifeSciences Holdings, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
415
Office Location:
10770 Wateridge Circle,Suite 200,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Directors

Name
Position
Bernd Brust
Chief Executive Officer and Director
R. Andrew Eckert
Chairman of the Board and Director
Constantine Mihas
Director
Gregory T. Lucier
Director
John DeFord
Director
Luke Marker
Director
Sean Cunningham
Director
Susannah Gray
Director

Shareholders

Name
Position
Bernd Brust
Chief Executive Officer and Director
Raj Asarpota
Chief Financial Officer
Christine Dolan
Executive Vice President
Kurt Oreshack
Executive Vice President and General Counsel and Secretary